In Brief: Epinephrine 1 mg Nasal Spray (neffy)

The FDA has approved a 1-mg epinephrine nasal spray (neffy - ARS Pharma) for emergency treatment of type 1 hypersensitivity reactions including anaphylaxis in patients ≥4 years old who weigh 15 to <30 kg. A 2-mg formulation of neffy was approved in 2024 for use in patients who weigh ≥30 kg.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-04-28
DOI: https://doi.org/10.58347/tml.2025.1727c
Citations: 1
Primary Topic: Poisoning and overdose treatments
Type: article
Field-Weighted Citation Impact: 2.25

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

In Brief: Epinephrine 1 mg Nasal Spray (neffy)

Apr 28, 2025

1 citations

The medical letter on drugs and therapeutics/The medical letter

Poisoning and overdose treatments

2.25

article

In Brief: Epinephrine 1 mg Nasal Spray (neffy)

April 28, 2025article en

1 citations

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1727)

Openalex Percentile: Top 15%

Poisoning and overdose treatments

2.25

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In Brief: Epinephrine 1 mg Nasal Spray (neffy) · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS